CRESCENT BIOPHARMA, INC. Financial and Nonfinancial Liabilities, Fair Value Disclosure
CRESCENT BIOPHARMA, INC. (CBIO) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $0 as of 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Notes › Fair Value Disclosures
us-gaap:LiabilitiesFairValueDisclosure · last filed 2019-03-06
- 2018-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2017-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2016-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2015-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-06 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-06 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-06 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |